Asset profile
AZD4144
Small molecule
Evidence outlook · lead readout
NCT06693765 · Renal Impairment, End-stage Kidney Disease, Healthy Participants
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT06693765: This was an unblinded, non-randomized study comparing drug levels across different kidney-function groups rather than testing the drug against a control treatment, so it does not provide controlled evidence of clinical benefit.
Also in development:Atherosclerotic Cardiovascular Disease · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.